Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease

A SUSTAIN study analysis

Abdullah Kutlar, Julie Kanter, Darla K. Liles, Ofelia A. Alvarez, Rodolfo D. Cançado, João R. Friedrisch, Jennifer M. Knight-Madden, Andreas Bruederle, Michael Shi, Zewen Zhu, Kenneth I. Ataga

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The cell adhesion molecule P-selectin plays a key role in the pathogenesis of a vaso-occlusive crisis (VOC) in patients with sickle cell disease (SCD). In the double-blind, placebo-controlled phase 2 SUSTAIN study, crizanlizumab (humanized, anti-P-selectin monoclonal antibody) 5 mg/kg significantly lowered the rate of VOC in patients with SCD by 45% vs placebo. In SUSTAIN, patients with SCD were randomized to crizanlizumab 2.5 mg/kg, crizanlizumab 5 mg/kg, or placebo intravenously 14 times over 52 weeks. The primary endpoint was the annual rate of VOC with crizanlizumab vs placebo. This post hoc descriptive analysis evaluated the proportion of patients who did not experience a VOC during the study in the following subgroups: VOCs in the year prior to study entry (2-4/5-10), SCD genotype (HbSS/non-HbSS), and concomitant hydroxyurea use (yes/no). More patients were VOC event-free in the crizanlizumab 5 mg/kg arm than in the placebo arm, including those with more frequent prior VOCs (ie, 5-10; 28.0% vs 4.2%), the HbSS genotype (31.9% vs 17.0%) and/or using concomitant hydroxyurea (33.3% vs 17.5%). Further analyses of secondary endpoints demonstrated that crizanlizumab treatment significantly increased time-to-first VOC vs placebo in these subgroups. The rates of treatment-emergent adverse events were similar between treatment arms across all subgroups. This post hoc analysis of SUSTAIN shows that in patients with a high number of prior VOCs, on concomitant hydroxyurea and/or with the HbSS genotype, crizanlizumab treatment increases the likelihood of patients being VOC event-free and delays time-to-first VOC.

Original languageEnglish (US)
Pages (from-to)55-61
Number of pages7
JournalAmerican Journal of Hematology
Volume94
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Sickle Cell Anemia
Pain
Placebos
Hydroxyurea
P-Selectin
Genotype
Cell Adhesion Molecules
Therapeutics
Monoclonal Antibodies

ASJC Scopus subject areas

  • Hematology

Cite this

Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease : A SUSTAIN study analysis. / Kutlar, Abdullah; Kanter, Julie; Liles, Darla K.; Alvarez, Ofelia A.; Cançado, Rodolfo D.; Friedrisch, João R.; Knight-Madden, Jennifer M.; Bruederle, Andreas; Shi, Michael; Zhu, Zewen; Ataga, Kenneth I.

In: American Journal of Hematology, Vol. 94, No. 1, 01.01.2019, p. 55-61.

Research output: Contribution to journalArticle

Kutlar, A, Kanter, J, Liles, DK, Alvarez, OA, Cançado, RD, Friedrisch, JR, Knight-Madden, JM, Bruederle, A, Shi, M, Zhu, Z & Ataga, KI 2019, 'Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis', American Journal of Hematology, vol. 94, no. 1, pp. 55-61. https://doi.org/10.1002/ajh.25308
Kutlar, Abdullah ; Kanter, Julie ; Liles, Darla K. ; Alvarez, Ofelia A. ; Cançado, Rodolfo D. ; Friedrisch, João R. ; Knight-Madden, Jennifer M. ; Bruederle, Andreas ; Shi, Michael ; Zhu, Zewen ; Ataga, Kenneth I. / Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease : A SUSTAIN study analysis. In: American Journal of Hematology. 2019 ; Vol. 94, No. 1. pp. 55-61.
@article{d784d3f78fe4460cab2936da9b1263bf,
title = "Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis",
abstract = "The cell adhesion molecule P-selectin plays a key role in the pathogenesis of a vaso-occlusive crisis (VOC) in patients with sickle cell disease (SCD). In the double-blind, placebo-controlled phase 2 SUSTAIN study, crizanlizumab (humanized, anti-P-selectin monoclonal antibody) 5 mg/kg significantly lowered the rate of VOC in patients with SCD by 45{\%} vs placebo. In SUSTAIN, patients with SCD were randomized to crizanlizumab 2.5 mg/kg, crizanlizumab 5 mg/kg, or placebo intravenously 14 times over 52 weeks. The primary endpoint was the annual rate of VOC with crizanlizumab vs placebo. This post hoc descriptive analysis evaluated the proportion of patients who did not experience a VOC during the study in the following subgroups: VOCs in the year prior to study entry (2-4/5-10), SCD genotype (HbSS/non-HbSS), and concomitant hydroxyurea use (yes/no). More patients were VOC event-free in the crizanlizumab 5 mg/kg arm than in the placebo arm, including those with more frequent prior VOCs (ie, 5-10; 28.0{\%} vs 4.2{\%}), the HbSS genotype (31.9{\%} vs 17.0{\%}) and/or using concomitant hydroxyurea (33.3{\%} vs 17.5{\%}). Further analyses of secondary endpoints demonstrated that crizanlizumab treatment significantly increased time-to-first VOC vs placebo in these subgroups. The rates of treatment-emergent adverse events were similar between treatment arms across all subgroups. This post hoc analysis of SUSTAIN shows that in patients with a high number of prior VOCs, on concomitant hydroxyurea and/or with the HbSS genotype, crizanlizumab treatment increases the likelihood of patients being VOC event-free and delays time-to-first VOC.",
author = "Abdullah Kutlar and Julie Kanter and Liles, {Darla K.} and Alvarez, {Ofelia A.} and Can{\cc}ado, {Rodolfo D.} and Friedrisch, {Jo{\~a}o R.} and Knight-Madden, {Jennifer M.} and Andreas Bruederle and Michael Shi and Zewen Zhu and Ataga, {Kenneth I.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/ajh.25308",
language = "English (US)",
volume = "94",
pages = "55--61",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease

T2 - A SUSTAIN study analysis

AU - Kutlar, Abdullah

AU - Kanter, Julie

AU - Liles, Darla K.

AU - Alvarez, Ofelia A.

AU - Cançado, Rodolfo D.

AU - Friedrisch, João R.

AU - Knight-Madden, Jennifer M.

AU - Bruederle, Andreas

AU - Shi, Michael

AU - Zhu, Zewen

AU - Ataga, Kenneth I.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The cell adhesion molecule P-selectin plays a key role in the pathogenesis of a vaso-occlusive crisis (VOC) in patients with sickle cell disease (SCD). In the double-blind, placebo-controlled phase 2 SUSTAIN study, crizanlizumab (humanized, anti-P-selectin monoclonal antibody) 5 mg/kg significantly lowered the rate of VOC in patients with SCD by 45% vs placebo. In SUSTAIN, patients with SCD were randomized to crizanlizumab 2.5 mg/kg, crizanlizumab 5 mg/kg, or placebo intravenously 14 times over 52 weeks. The primary endpoint was the annual rate of VOC with crizanlizumab vs placebo. This post hoc descriptive analysis evaluated the proportion of patients who did not experience a VOC during the study in the following subgroups: VOCs in the year prior to study entry (2-4/5-10), SCD genotype (HbSS/non-HbSS), and concomitant hydroxyurea use (yes/no). More patients were VOC event-free in the crizanlizumab 5 mg/kg arm than in the placebo arm, including those with more frequent prior VOCs (ie, 5-10; 28.0% vs 4.2%), the HbSS genotype (31.9% vs 17.0%) and/or using concomitant hydroxyurea (33.3% vs 17.5%). Further analyses of secondary endpoints demonstrated that crizanlizumab treatment significantly increased time-to-first VOC vs placebo in these subgroups. The rates of treatment-emergent adverse events were similar between treatment arms across all subgroups. This post hoc analysis of SUSTAIN shows that in patients with a high number of prior VOCs, on concomitant hydroxyurea and/or with the HbSS genotype, crizanlizumab treatment increases the likelihood of patients being VOC event-free and delays time-to-first VOC.

AB - The cell adhesion molecule P-selectin plays a key role in the pathogenesis of a vaso-occlusive crisis (VOC) in patients with sickle cell disease (SCD). In the double-blind, placebo-controlled phase 2 SUSTAIN study, crizanlizumab (humanized, anti-P-selectin monoclonal antibody) 5 mg/kg significantly lowered the rate of VOC in patients with SCD by 45% vs placebo. In SUSTAIN, patients with SCD were randomized to crizanlizumab 2.5 mg/kg, crizanlizumab 5 mg/kg, or placebo intravenously 14 times over 52 weeks. The primary endpoint was the annual rate of VOC with crizanlizumab vs placebo. This post hoc descriptive analysis evaluated the proportion of patients who did not experience a VOC during the study in the following subgroups: VOCs in the year prior to study entry (2-4/5-10), SCD genotype (HbSS/non-HbSS), and concomitant hydroxyurea use (yes/no). More patients were VOC event-free in the crizanlizumab 5 mg/kg arm than in the placebo arm, including those with more frequent prior VOCs (ie, 5-10; 28.0% vs 4.2%), the HbSS genotype (31.9% vs 17.0%) and/or using concomitant hydroxyurea (33.3% vs 17.5%). Further analyses of secondary endpoints demonstrated that crizanlizumab treatment significantly increased time-to-first VOC vs placebo in these subgroups. The rates of treatment-emergent adverse events were similar between treatment arms across all subgroups. This post hoc analysis of SUSTAIN shows that in patients with a high number of prior VOCs, on concomitant hydroxyurea and/or with the HbSS genotype, crizanlizumab treatment increases the likelihood of patients being VOC event-free and delays time-to-first VOC.

UR - http://www.scopus.com/inward/record.url?scp=85057262002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057262002&partnerID=8YFLogxK

U2 - 10.1002/ajh.25308

DO - 10.1002/ajh.25308

M3 - Article

VL - 94

SP - 55

EP - 61

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -